First patient enrolled in new Phase 3 Trial program investigating a once-daily dosing regimen of Isentress (raltegravir)

06-06-2014 Business Wire HealthComments (0)

IsentressPharmaceuticalUSA

First patient enrolled in new Phase 3 Trial program investigating a once-daily dosing regimen of Isentress (raltegravir). ONCEMRK Study Globally Enrolling Treatment-Naïve Adults with HIV-1.

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top